Pyrimidinyl tyrosine kinase inhibitors
US-9394277-B2 · Jul 19, 2016 · US
Inhibitors of Bruton's tyrosine kinase
US10189817B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10189817-B2 |
| Application number | US-201815875629-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2018 |
| Priority date | Jun 8, 2012 |
| Publication date | Jan 29, 2019 |
| Grant date | Jan 29, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of formula A: wherein —OR LG is a suitable leaving group. 2. A compound of formula B: wherein —OR LG is a suitable leaving group. 3. The compound of claim 1 , wherein —OR LG is a C 1-6 aliphatic alkoxy group. 4. The compound of claim 1 , wherein —OR LG is ethoxy or t-butoxy. 5. The compound of claim 2 , wherein —OR LG is a C 1-6 aliphatic alkoxy group. 6. The compound of claim 2 , wherein —OR LG is ethoxy or t-butoxy.
Assignees
Inventors
Classifications
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
Crystalline forms, e.g. polymorphs · CPC title
2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10189817B2 cover?
- The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.
- Who is the assignee on this patent?
- Biogen Ma Inc, Sunesis Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).